alpha clash anti-IL-2 antibody fusion protein LAT010

An antibody fusion protein and interleukin-2 (IL-2) immunocytokine, with potential antineoplastic activity. Upon administration of the alpha-clash anti-IL-2 antibody fusion protein LAT010, the IL-2 moiety targets and binds to the intermediate-affinity IL-2 receptor beta,gamma (IL-2Rbg), thereby selectivity activating CD8+ T cells and natural killer (NK) cells against tumor cells. The alpha-clash anti-IL-2 antibody moiety of LAT010 prevents LAT010 from activating the high-affinity IL2Ralpha,beta,gamma receptor complex which may prevent severe IL-2-mediated systemic toxic effects.